Adverse effects on perineal wound healing: Day 5 ‐ Wound not healing · Women with perineal trauma (tear or episiotomy, or both) sustained during childbirth
It is very uncertain whether cooling treatment (ice pack or cold gel pad) changes adverse effects on perineal wound healing: Day 5 ‐ Wound not healing compared with no treatment (very low certainty).
1 finding from 1 review
Adverse effects on perineal wound healing: Day 5 ‐ Wound not healing · Women with perineal trauma (tear or episiotomy, or both) sustained during childbirth
It is very uncertain whether cooling treatment (ice pack) changes adverse effects on perineal wound healing: Day 5 ‐ Wound not healing compared with cooling treatment (cold gel pad) (very low certainty).
1 finding from 1 review
Adverse effects on perineal wound healing: Day 5 ‐ Wound edges gaping · Women with perineal trauma (tear or episiotomy, or both) sustained during childbirth
It is very uncertain whether cooling treatment (ice pack or cold gel pad) changes adverse effects on perineal wound healing: Day 5 ‐ Wound edges gaping compared with no treatment (very low certainty).
1 finding from 1 review
Adverse effects on perineal wound healing: Day 5 ‐ Wound edges gaping · Women with perineal trauma (tear or episiotomy, or both) sustained during childbirth
It is very uncertain whether cooling treatment (ice pack) changes adverse effects on perineal wound healing: Day 5 ‐ Wound edges gaping compared with cooling treatment (cold gel pad) (very low certainty).
1 finding from 1 review
Adverse effects · People with avulsed and replanted permanent (front) teeth
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Clofazimine was associated with an increase in cutaneous adverse effects (Fisher's exact test P=0.015), easily controlled; there was a greater percentage of treatment interruptions in the colchicine group due to…
1 study · 46 participants
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Colchicine was associated with statistically significantly more adverse effects than prednisolone (nine participants reporting adverse effects on colchicine versus two on prednisolone).
1 study · 34 participants
GRADE not reported
Adverse effects · People with avulsed and replanted permanent (front) teeth
1 finding from 1 review
Day 2012 used a formal methodology to identify and report adverse effects, with none identified.
1 study · 22 participants
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with low dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus low dose (greater than or… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus standard‐lower dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) probably leads to lower adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
LOW DOSE (greater than or equal to 2‐<4 mg/day) showed no clear difference in adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS:… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Tremor · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐ tremor… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ dystonia ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐LOWER DOSE (greater than or equal to 4‐<6 mg/day) probably leads to higher adverse effects: 6. Movement disorders ‐ specific symptoms ‐… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review